Arrested spread of vesicular stomatitis virus infections in vitro depends on interferon-mediated antiviral activity

Biotechnology and Bioengineering

Volumn 90, Issue 7, 2005, Pages 793-804

  Lam, Vy ^a   Duca, Karen A ^a,b   Yin, John ^a  

^a University of Wisconsin Madison   (United States)

^b VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

Antiviral responses; Infection spread; Interferon signaling; Vesicular stomatitis virus; Virus host interactions

Indexed keywords

ANTIBODIES; GENES; GROWTH KINETICS; IMMUNOLOGY; MONOLAYERS; TUMORS;

ANTIVIRAL ACTIVITIES; DELAYED BRAIN TUMOR (DBT); GENE EXPRESSION; VESICULAR STOMATITIS VIRUS (VSV);

VIRUSES;

INTERFERON; INTERFERON ANTIBODY;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN TUMOR; CELL DEATH; CELL SPREADING; CELL STRAIN BHK; GENE EXPRESSION; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; BRAIN NEOPLASMS; CELLS, CULTURED; CRICETINAE; INTERFERONS; MICE; RHABDOVIRIDAE INFECTIONS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

CRICETINAE; VESICULAR STOMATITIS VIRUS;

EID: 19944402918     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20467     Document Type: Article

References (31)

1. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. 2003. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77(8):4646-4657.
2. Andzhaparidze OG, Bogomolova NN, Boriskin YS, Bektemirova MS, Drynov ID. 1981. Comparative study of rabies virus persistence in human and hamster cell lines. J Virol 37(1):1-6.
3. Arnheiter H, Davis NL, Wertz G, Schubert M, Lazzarini RA. 1985. Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis. Cell 41(1):259-267.
4. Balachandran S, Barber GN. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50(2):135-138.
5. Ball LA, Pringle CR, Flanagan B, Perepelitsa VP, Wertz GW. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73(6):4705-4712.
6. Black BL, Lyles DS. 1992. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol 66(7): 4058-4064.
7. Black BL, Rhodes RB, McKenzie M, Lyles DS. 1993. The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol 67(8):4814-4821.
8. Coulon P, Deutsch V, Lafay F, Martinet-Edelist C, Wyers F, Herman RC, Flamand A. 1990. Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J Gen Virol 71(Pt 4):991-996.
9. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ. 1996. Basic concepts in RNA virus evolution. FASEB Journal 10(8):859-864.
10. Duca KA, Lam V, Keren I, Endler EE, Letchworth GJ, Novella IS, Yin J. 2001. Quantifying viral propagation in vitro: toward a method for characterization of complex phenotypes. Biotechnol Prog 17(6):1156-1165.
11. Fernandez M, Porosnicu M, Markovic D, Barber GN. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol 76(2):895-904.
12. Ferran MC, Lucas-Lenard JM. 1997. The vesicular stomatitis virus matrix protein inhibits transcription from the human beta Interferon promoter. J Virol 71(1):371-377.
13. Flanagan EB, Zamparo JM, Ball LA, Rodriguez LL, Wertz GW. 2001. Re-arrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: New strategy for vaccine development. J Virol 75(13):6107-6114.
14. Francoeur AM, Lam T, Stanners CP. 1980. PIF, a highly sensitive plaque assay for the induction of interferon. Virology 105(2):526-536.
15. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. 1982. Rapid evolution of RNA genomes. Science 215(4540):1577-1585.
16. Kopecky SA, Willingham MC, Lyles DS. 2001. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 75(24):12169-12181.
17. Kramer MJ, Dennin R, Kramer C, Jones G, Connell E, Rolon N, Gruarin A, Kale R, Trown PW. 1983. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 3(4):425-435.
18. Lenard J. 1999. Host cell protein kinases in nonsegmented negative-strand virus (mononegavirales) infection. Pharmacol Ther 83(1):39-48.
19. Letchworth GJ, Rodriguez LL, Del cbarrera J. 1999. Vesicular stomatitis. Vet J 157(3):239-260.
20. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. 2003. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 1(2):229-237.
21. Nagai Y, Ho Y, Hamaguchi M, Yoshida T, Matsumoto T. 1981. Relation of interferon production to the limited replication of Newcastle disease virus in L cells. J Gen Virol 55(Pt 1):109-116.
22. Otsuki K, Maeda J, Yamamoto H, Tsubokura M. 1979. Studies on avian infectious bronchitis virus (IBV). III. Interferon induction by and sensitivity to Interferon of IBV. Arch Virol 60(3-4):249-255.
23. Patton JT, Davis NL, Wertz GW. 1984. N protein alone satisfies the requirement for protein synthesis during RNA replication of vesicular stomatitis virus. J Virol 49(2):303-309.
24. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, Montefiori D, Earl P, Moss B, Rose JK. 2004. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78(8):3930-3940.
25. Roberts A, Buonocore L, Price R, Forman J, Rose JK. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73(5):3723-3732.
26. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, Kawaoka Y, Rose JK. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72(6):4704-4711.
27. Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK. 2004. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78(6):3196-3199.
28. van den Pol AN, Dalton KP, Rose JK. 2002. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 76(3):1309-1327.
29. Wagner RR, Levey AH, Snyder RM, Ratcliff GA Jr., Hyatt DF. 1963. Biologic properties of two plaque variants of vesicular stomatitis virus (Indiana serotype). J Immunol 91:112-122.
30. Wertz GW, Perepelitsa VP, Ball LA. 1998. Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95(7):3501-3506.
31. Zerial A, Hovanessian AG, Stefanos S, Huygen K, Werner GH, Falcoff E. 1982. Synergistic activities of type I (alpha, beta) and type II (gamma) murine interferons. Antiviral Res 2(4):227-239.